{"denoms":[{"counts":[{"groupId":"BG000","value":"29"}],"units":"Participants"}],"groups":[{"description":"Single dose Zoledronic Acid (Zoledronate) 4mg IV over at least 15 minutes (or dose corrected for creatinine clearance x1) followed by Aminobisphosphonates (aBP) cessation during study period","id":"BG000","title":"Zoledronic Acid"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"46","upperLimit":"85","value":"60"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Stage III"}],"description":"International Staging System (ISS) stage","paramType":"NUMBER","title":"ISS Stage","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Bortezomib + lenalidomide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Bortezomib + Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Therapy","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"No"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Autologous Transplant","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"> 3 bone lesions"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"≤ 3 bone lesions"}],"paramType":"NUMBER","title":"Bone Lesions","unitOfMeasure":"participants"}]}